Nanoform, a nanoparticle medicine company, has signed an agreement with a European headquartered international company to manufacture GMP nanoformed material for an improved version of a current "blockbuster" drug.
In Q3 the company signed six customer non-GMP projects, taking the total non-GMP project count for 2021 so far to 14 and achieving its near-term business target. The announced GMP agreement is for early clinical development and therefore in the lower end of the company GMP guidance range. The final contractual terms for commercialisation will be negotiated as the project progresses.
Prof Edward Hæggström, CEO of Nanoform, commented: “Following our clinical results earlier this year, Nanoform now enters its next growth phase; manufacture of nanoformed clinical grade APIs for our customers and partners. Our manufacturing expansion is on track and in the coming years we’ll have additional GMP lines in place, catering to our customers’ growing needs for nanoformed APIs.”
